The latest research included in the proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) means that antibiotic treatments and management therapies feature strongly in DrugResearcher’s round-up of the 4-day event.
The gathering is a chance for scientists
and cancer researchers, as well as pharmaceutical and biotechnology
companies from around the world to present the latest in scientific
research to the attending microbiological community.
The meeting, which is taking place in Washington DC, was used to
present data from Elusys Therapeutics, which described results of two
preclinical studies of ETI-211, the Company’s Heteropolymer (HP)
antibody drug candidate targeting methicillin-resistant Staphylococcus
aureus (MRSA) infections.
.gif)
0 responses so far ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment